INTRODUCTION

Parallel to the development of novel therapies, there have been multiple attempts to treat COVID-19 using repurposed drugs, including corticosteroids, remdesivir, and tocilizumab. Some candidates have raised much controversy, especially hydroxychloroquine, which had been initially widely used but was eventually shown to be ineffective in several randomized trials.\(^1\) The antiparasitic ivermectin recently gained support as a new therapeutic agent for COVID-19.\(^2\) However, the World Health Organization, US Food and Drug Administration, European Medicines Agency, and Merck, the drug’s manufacturer, all advised against using ivermectin outside clinical trials\(^3\) since high dosages would be required for antiviral activity, increasing the risk of adverse events (AEs). Although ivermectin has a good safety profile...
in the recommended dosages, some rare events may go undetected in clinical trials or retrospective cohorts. Therefore, postmarketing surveillance data, aggregated from spontaneous reports, is a useful tool for investigating rare AEs and severe cutaneous adverse reactions (SCARs) in particular.

2 METHODS

This was a retrospective analysis of postmarketing safety data from the FDA Adverse Event Reporting System (FAERS), collected between July 2014 and June 2021. FAERS utilizes the Medical Dictionary for Regulatory Activities (MedDRA), a hierarchical and rigorously maintained standardized terminology of medical concepts. Duplicate reports were recognized as those with overlaps in at least three out of four key fields: date, age, gender, and country. We selected reports in which orally administered ivermectin was the primary suspect and adopted a conservative approach by assuming topical ivermectin was used in cases where the indication was lice infestation, acarodermatitis, or rosacea and the route of administration was unknown. Acarodermatitis is a MedDRA term that may be used to indicate any of the following conditions: acarodermatitis, Norwegian scabies, Sarcoptes scabiei infestation, scabies, and scabies infestation. Severe cutaneous adverse reactions (SCARs) were defined according to the Standardized MedDRA Query (SMQ). If a case reported both Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), it was considered only as TEN, since these conditions lie on a disease spectrum.

We employed a disproportionality analysis to estimate safety signals from spontaneous AE reports, using the validated reporting odds ratio (ROR), which is the odds of reporting a specific AE versus all other AEs under a certain product, compared to all other products available in FAERS. The ROR is analogous to the odds ratio (ROR), which is the odds of reporting a specific AE versus all other AEs under a certain product, compared to all other products available in FAERS. The ROR is analogous to the odds ratio in a case-control study where the exposure is ivermectin and the outcome is reporting of SCAR. Multivariate logistic regression was performed using age, sex, and ivermectin use as covariates. Disproportionality analysis (Table 2) revealed that ivermectin was significantly associated with reporting of any SCAR (crude ROR 4.34, 95% confidence interval [CI] 2.84–6.64). The association was still evident after adjusting for age, sex, and region (adjusted ROR 3.34, 95% CI 2.17–5.12, P < 0.001). Age under 60 (adjusted ROR 1.28, 95% CI 1.26–1.29, P < 0.001) and female sex (adjusted ROR 1.27, 95% CI 1.25–1.29, P < 0.001) were also correlated with SCAR reporting to a lesser degree. When using toxidermias (TEN, SJS, DRESS, and acute generalized exanthematous pustulosis) as a binary outcome, the association with ivermectin was more pronounced (crude ROR 15.4, 95% CI 9.3–25.48, P < 0.001), even when correcting for other covariates (adjusted ROR 7.08, 95% CI 4.23–11.84, P < 0.001).

3 RESULTS

The search yielded 517 reports of systemic ivermectin (median age 54 years, interquartile range [IQR] 33.5–70.5 years, 46.8% female), of which 25 (4.8%), 81 (15.7%), and 411 (79.5%) were classified as SCARs, nonsevere cutaneous AEs, or noncutaneous AEs, respectively (Table 1). Within SCAR cases, the median age was 43 years (IQR 29–69.25 years) and 48.0% were female. The median dosage was 9 mg (IQR 3.75–12 mg) and the median time to onset was 3 days (IQR 1.5–7.25 days), although this information was missing for more than half of cases. Age and sex did not differ between the three groups (P = 0.355 for age comparison, P = 0.178 for sex comparison), as well as dose and time to onset (P = 0.075 and P = 0.270, respectively). SCAR cases originated from Africa (8/25 cases, 32.0%), Europe (7/25 cases, 28.0%), Asia (6/25 cases, 24.0%), and North America (3/25 cases, 12.0%). This was in contrast to the other cases, which originated from North America in over 50% of cases, but from Africa in less than 10% of cases (χ² = 25.85, P < 0.001).

The most common indications were acarodermatitis due to mite infestation and helminthic infections, including filariasis, onchocerciasis, and strongyloidiasis. In a few cases concomitant drugs previously associated with SCARs were reported as secondary suspects (two cases of amoxicillin and one case of valproic acid). The most common SCARs were TEN, SJS, and drug reaction with eosinophilia and systemic symptoms (DRESS), occurring in seven (28.0%), seven (8.0%), and four (16.0%) cases, respectively (Figure 1). Among SCAR cases, five (20.0%) resulted in death and 12 (48.0%) in hospitalization. The most common nonsevere cutaneous AEs were pruritus (31 cases, 38.3%), rash (16 cases, 19.8%), and angioedema (11 cases, 13.6%). Death was reported in four cases (4.9%) of nonsevere cutaneous AEs, but was due to other co-occurring AEs such as sepsis or other organ failure.

Disproportionality analysis (Table 2) revealed that ivermectin was significantly associated with reporting of any SCAR (crude ROR 4.34, 95% confidence interval [CI] 2.84–6.64). The association was still evident after adjusting for age, sex, and region (adjusted ROR 3.34, 95% CI 2.17–5.12, P < 0.001). Age under 60 (adjusted ROR 1.28, 95% CI 1.26–1.29, P < 0.001) and female sex (adjusted ROR 1.27, 95% CI 1.25–1.29, P < 0.001) were also correlated with SCAR reporting to a lesser degree. When using toxidermias (TEN, SJS, DRESS, and acute generalized exanthematous pustulosis) as a binary outcome, the association with ivermectin was more pronounced (crude ROR 15.4, 95% CI 9.3–25.48, P < 0.001), even when correcting for other covariates (adjusted ROR 7.08, 95% CI 4.23–11.84, P < 0.001).

4 DISCUSSION

Ivermectin has been used for more than three decades for treating filariasis, onchocerciasis, and strongyloidiasis in humans, as well as other dermatologic conditions such as scabies, lice infestation, or demodicosis. While generally safe at recommended dosages, ivermectin may lead to pruritus, lymphadenitis, arthralgia, and fever, sometimes as part of the Mazzotti reaction. Although the most serious ivermectin safety concern is rare neurotoxicity, several cases of SCARs following systemic ivermectin have been reported in recent years. Our search yielded 25 cases of ivermectin-related SCARs, mostly SJS, TEN, and DRESS, with a 20% mortality. Disproportionality analysis revealed a significant association between systemic ivermectin and reporting of any SCARs, confirming a recent study of VigiBase, another pharmacovigilance database. Interestingly, SCARs were reported more in African countries.
### TABLE 1  All cases of systemic ivermectin reported to FAERS, 2014 to 2021

|                        | Severe cutaneous adverse reactions | Nonsevere cutaneous adverse events | Noncutaneous adverse events | P<sub>a</sub> |
|------------------------|------------------------------------|------------------------------------|-----------------------------|--------------|
| **Total, n**           | 25                                 | 81                                 | 411                         |              |
| **Age, years (median [IQR])** | 43 [29, 69.25]                    | 50 [31, 66]                        | 55 [35, 72]                 | 0.355        |
| **Sex, n (%)**         |                                    |                                    |                             |              |
| Female                 | 12 (48.0)                          | 41 (50.6)                          | 189 (46.0)                  | 0.178        |
| Male                   | 12 (48.0)                          | 23 (28.4)                          | 156 (38.0)                  |              |
| Unknown                | 1 (4.0)                            | 17 (21.0)                          | 66 (16.1)                   |              |
| **Region, n (%)**      |                                    |                                    |                             |              |
| Africa                 | 8 (32.0)                           | 8 (9.9)                            | 36 (8.8)                    | 0.004        |
| Asia                   | 6 (24.0)                           | 11 (13.6)                          | 57 (13.9)                   |              |
| Europe                 | 7 (28.0)                           | 14 (17.3)                          | 69 (16.8)                   |              |
| North America          | 3 (12.0)                           | 45 (55.6)                          | 238 (57.9)                  |              |
| Oceania                | 0 (0.0)                            | 0 (0.0)                            | 4 (1.0)                     |              |
| South America          | 0 (0.0)                            | 1 (1.2)                            | 2 (0.5)                     |              |
| Unknown                | 1 (4.0)                            | 2 (2.5)                            | 5 (1.2)                     |              |
| **Dose, mg (median [IQR])** | 9 [3.75, 12]                    | 10.5 [6, 12]                       | 12 [9, 12]                  | 0.075        |
| Onset, days (median, [IQR]) | 3 [1.5, 7.25]                  | 3.5 [1, 10.5]                      | 2 [0, 7]                    | 0.270        |
| **Indication, n (%)**  |                                    |                                    |                             |              |
| Acarodermatitis        | 12 (48.0)                          | 32 (39.5)                          | 110 (26.8)                  | 0.490        |
| Helminthic infection   | 8 (32.0)                           | 13 (16.0)                          | 119 (29.0)                  |              |
| Infection prophylaxis  | 1 (4.0)                            | 1 (1.2)                            | 21 (5.1)                    |              |
| Lice infestation       | 1 (4.0)                            | 2 (2.5)                            | 6 (1.5)                     |              |
| COVID-19               | 0 (0.0)                            | 1 (1.2)                            | 27 (6.6)                    |              |
| Unknown                | 3 (12.0)                           | 24 (29.6)                          | 91 (22.1)                   |              |
| **Adverse events, n (%)** |                                  |                                    |                             |              |
| Stevens-Johnson syndrome; 7 (28) |                          | Pruritus; 31 (38.3)            | Altered mental status; 26 (6.3) |              |
| Toxic epidermal necrolysis; 7 (28) |                          | Rash; 16 (19.8)                 | Ocular/visual AE; 23 (5.6) |              |
| DRESS; 4 (16)          |                                    |                                   | Nausea/vomiting; 21 (5.1)  |              |
| Oral blister/ulcer; 3 (12) |                          |                                   | Balance disorder; 20 (4.9) |              |
| Erythema multiforme; 2 (8) |                          |                                   | Headache; 20 (4.9)         |              |
| Skin exfoliation; 2 (8) |                                    |                                    | Erythema; 6 (7.4)          |              |
| Alopecia; 4 (4.9)       |                                    |                                    | Erythema; 6 (7.4)          |              |
| AGEP; 1 (4)            |                                    |                                    | Alopecia; 4 (4.9)          |              |
| Bullous dermatitis; 1 (4) |                          |                                    | Headache; 20 (4.9)         |              |
| Exfoliative dermatitis; 1 (4) |                          |                                    | Erythema; 6 (7.4)          |              |
| Pemphigoid; 1 (4)       |                                    |                                    | Erythema; 6 (7.4)          |              |
| SDRIFE; 1 (4)          |                                    |                                    | Erythema; 6 (7.4)          |              |
| Toxic skin eruption; 1 (4) |                          |                                    | Erythema; 6 (7.4)          |              |
| **Outcome, n (%)**     |                                    |                                    |                             |              |
| Death                  | 5 (20.0)                           | 4 (4.9)                            | 36 (8.8)                    | 0.001        |
| Life-threatening        | 1 (4.0)                            | 1 (1.2)                            | 5 (1.2)                     |              |
| Hospitalization        | 12 (48.0)                          | 20 (24.7)                          | 93 (22.6)                   |              |
| Disability             | 3 (12.0)                           | 2 (2.5)                            | 14 (3.4)                    |              |
| Other serious          | 4 (16.0)                           | 12 (14.8)                          | 80 (19.5)                   |              |
| Unknown                | 0 (0.0)                            | 42 (51.9)                          | 183 (44.5)                  |              |

(Continues)
compared to other cutaneous AEs. This could be explained by under-reporting of milder cutaneous AEs in these countries compared with North American or European countries, or by increased incidence of HIV carriers in Africa, which is a risk factor for some SCARs, in particular SJS and TEN.

This work has several limitations, inherent to any analysis of spontaneous AE reports, such as missing data, under-reporting, and lack of clinical information. Another important limitation is indication bias, where cases of pruritus reflect the indication (scabies-related pruritus), rather than the AE. Moreover, the ROR does not represent the incidence of any particular AE, since the total number of individuals treated with ivermectin is unknown. The data cannot be automatically applied to use in COVID-19 since no SCARs were recorded in this recent setting. Although we focused on reports in which ivermectin was the primary suspect drug, in three out 25 SCAR cases there was concomitant use of secondary suspects known to cause SCARs, which weakens the possible association. Lastly, a causal relationship between drug exposure and the reported AE cannot be fully ascertained.

A major challenge of the current pandemic is the fight against the COVID-19 "infodemic", the dissemination of false or inaccurate information. Unfortunately, misleading data obtained from ivermectin studies with poor methodology continue to amass. This has led to a recent dramatic surge in calls to US poison-control centers by people who are self-medicating with ivermectin and, more alarmingly, self-dosing, as the drug is sold without

| Reporter's occupation, n (%) | Severe cutaneous adverse reactions | Nonsevere cutaneous adverse events | Noncutaneous adverse events | P^d |
|-------------------------------|------------------------------------|-----------------------------------|-----------------------------|-----|
| Physician                     | 14 (56.0)                          | 24 (29.6)                         | 117 (28.5)                  | 0.004|
| Consumer                      | 4 (16.0)                           | 38 (46.9)                         | 124 (30.2)                  |     |
| Pharmacist                    | 2 (8.0)                            | 5 (6.2)                           | 45 (10.9)                   |     |
| Other health professional     | 4 (16.0)                           | 14 (17.3)                         | 103 (25.1)                  |     |
| Unknown                       | 1 (4.0)                            | 0 (0.0)                           | 22 (5.4)                    |     |
| Year of reporting, n (%)      |                                    |                                   |                             |     |
| 2014                          | 1 (4.0)                            | 16 (19.8)                         | 20 (4.9)                    | <0.001|
| 2015                          | 5 (20.0)                           | 14 (17.3)                         | 61 (14.8)                   |     |
| 2016                          | 1 (4.0)                            | 8 (9.9)                           | 36 (8.8)                    |     |
| 2017                          | 2 (8.0)                            | 15 (18.5)                         | 66 (16.1)                   |     |
| 2018                          | 4 (16.0)                           | 5 (6.2)                           | 57 (13.9)                   |     |
| 2019                          | 9 (36.0)                           | 13 (16.0)                         | 69 (16.8)                   |     |
| 2020                          | 2 (8.0)                            | 5 (6.2)                           | 65 (15.8)                   |     |
| 2021                          | 1 (4.0)                            | 5 (6.2)                           | 37 (9.0)                    |     |

Abbreviations: AE, adverse event; AGEP, acute generalized exanthematous pustulosis; DRESS, drug reaction with eosinophilia and systemic symptoms; FAERS, FDA adverse event reporting system; IQR, interquartile range; LFT, liver function tests; SCAR, severe cutaneous adverse reaction; SDRIFE, symmetrical drug-related intertriginous and flexural exanthema.

^a Only indications with at least five cases are presented. Therefore, rows may not sum up to 100%.

^b Only AEs that comprise at least 3% of cases are presented. Therefore, rows may not sum up to 100%.

^c The primary reason of death, life-threatening scenario, hospitalization, or disability may be other co-occurring AEs.

^d The Kruskal–Wallis or χ² tests were used to compare continuous or categorical data across the three groups, respectively.

FIGURE 1 SCARs associated with systemic ivermectin reported to FAERS, 2014 to 2021. AGEP, acute generalized exanthematous pustulosis; DRESS, drug reaction with eosinophilia and systemic symptoms; FAERS, FDA adverse event reporting system; SCAR, severe cutaneous adverse reaction; SDRIFE, symmetrical drug-related intertriginous and flexural exanthema. *There were overall five SCAR cases where death was reported. There were two cases of Stevens-Johnson syndrome and three cases of toxic epidermal necrolysis, out of which one reported concomitant oral blister/ulcer and another reported concomitant DRESS compared to other cutaneous AEs.
In view of this emerging situation, dermatologists should be aware of ivermectin-associated SCARs.

**TABLE 2** Multivariate logistic regression analysis of severe cutaneous adverse reactions reported to FAERS, 2014 to 2021

| Covariate | n/total cases | Proportion (95% CI) | Crude ROR (95% CI) | Adjusted ROR (95% CI) | P |
|-----------|---------------|---------------------|--------------------|-----------------------|---|
| A | Any severe cutaneous adverse reactions | | |
| Ivermectin | | | |
| Nonuser | 83156/4445256 | 0.019 (0.019–0.019) | 1 (reference) | 1 (reference) | |
| User | 23/301 | 0.076 (0.051–0.112) | 4.34 (2.84–6.64) | 3.34 (2.17–5.12) | <0.001 |
| Age, years | | | |
| ≥60 | 34255/2060399 | 0.017 (0.016–0.017) | 1 (reference) | 1 (reference) | |
| <60 | 48924/2385158 | 0.021 (0.020–0.021) | 1.24 (1.22–1.26) | 1.28 (1.26–1.29) | <0.001 |
| Sex | | | |
| Male | 30003/1770624 | 0.017 (0.017–0.017) | 1 (reference) | 1 (reference) | |
| Female | 53176/2674933 | 0.020 (0.020–0.020) | 1.18 (1.16–1.19) | 1.27 (1.25–1.29) | <0.001 |
| Region | | | |
| North America | 45640/3173953 | 0.014 (0.014–0.015) | 1 (reference) | 1 (reference) | |
| Africa | 553/17367 | 0.032 (0.029–0.035) | 2.25 (2.07–2.45) | 2.20 (2.02–2.40) | <0.001 |
| Asia | 13007/339807 | 0.038 (0.038–0.039) | 2.73 (2.67–2.78) | 2.89 (2.84–2.95) | <0.001 |
| Europe | 21419/768491 | 0.028 (0.028–0.028) | 1.97 (1.93–2.00) | 2.03 (2.00–2.06) | <0.001 |
| Oceania | 753/37626 | 0.020 (0.019–0.021) | 1.40 (1.30–1.51) | 1.44 (1.34–1.55) | <0.001 |
| South America | 1807/108313 | 0.017 (0.016–0.017) | 1.16 (1.11–1.22) | 1.16 (1.11–1.22) | <0.001 |

B | Toxidermias: one of toxic epidermal necrolysis, Stevens–Johnson syndrome, DRESS, or AGEP | | |
| Ivermectin | | | |
| Nonuser | 16149/4445256 | 0.004 (0.004–0.004) | 1 (reference) | 1 (reference) | |
| User | 16/301 | 0.053 (0.033–0.085) | 15.4 (9.3–25.48) | 7.08 (4.23–11.84) | <0.001 |
| Age, years | | | |
| ≥60 | 6332/2060399 | 0.003 (0.003–0.003) | 1 (reference) | 1 (reference) | |
| <60 | 9833/2385158 | 0.004 (0.004–0.004) | 1.34 (1.3–1.39) | 1.49 (1.44–1.54) | <0.001 |
| Sex | | | |
| Male | 7238/1770624 | 0.004 (0.004–0.004) | 1 (reference) | 1 (reference) | |
| Female | 8927/2674933 | 0.003 (0.003–0.003) | 0.82 (0.79–0.84) | 1.0031 (0.9721–1.0351) | 0.844 |
| Region | | | |
| North America | 3749/3173953 | 0.001 (0.001–0.001) | 1 (reference) | 1 (reference) | |
| Africa | 348/17367 | 0.020 (0.018–0.022) | 17.29 (15.48–19.32) | 16.12 (14.42–18.02) | <0.001 |
| Asia | 3966/339807 | 0.012 (0.011–0.012) | 9.99 (9.55–10.44) | 10.33 (9.88–10.81) | <0.001 |
| Europe | 7518/768491 | 0.010 (0.010–0.010) | 8.35 (8.03–8.69) | 8.49 (8.17–8.84) | <0.001 |
| Oceania | 317/37626 | 0.008 (0.008–0.009) | 7.18 (6.4–8.06) | 7.23 (6.44–8.11) | <0.001 |
| South America | 267/108313 | 0.002 (0.002–0.003) | 2.09 (1.85–2.37) | 2.08 (1.84–2.36) | <0.001 |

Abbreviations: AGEP, acute generalized exanthematous pustulosis; CI, confidence interval; DRESS, drug reaction with eosinophilia and systemic symptoms; FAERS, FDA adverse event reporting system; ROR, reporting odds ratio; SCAR, severe cutaneous adverse reactions.

\*The entire FAERS database, excluding cases with missing covariates, was used to calculate a reporting odds ratio (ROR). The ROR is therefore analogous to an odds ratio in a case–control design, where the exposure is the drug (e.g., ivermectin) and the outcome is reporting of an AE of interest (e.g., SCAR or toxidermias).

\*Two cases originating from Antarctica were excluded, these did not report any SCARs.

**ACKNOWLEDGMENTS**

All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by D.B.
The first draft of the manuscript was written by D.B. and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

CONFLICT OF INTEREST
The authors report no conflict of interest.

ETHICAL APPROVAL
This study is based on anonymous data that can be downloaded from a publicly available source. Therefore, no ethical approval is required.

ORCID
David Bomze https://orcid.org/0000-0003-2958-7055
Shamir Geller https://orcid.org/0000-0003-1206-1057

REFERENCES
1. Axfors C, Schmitt AM, Janiaud P, van’t Hooft J, Abd-Elsalam S, Abdo EF, et al. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat Commun. 2021;12:2349.
2. Reardon S. Flawed ivermectin preprint highlights challenges of COVID drug studies. Nature. 2021;596:173–4.
3. WHO joins Europe, Merck in recommending against ivermectin for COVID-19. Reuters [Internet]. 2021 Mar 31. Available from: https://www.reuters.com/article/us-health-coronavirus-ivermectin-idUSKBN2BN2H
4. Poluzzi E, Raschi E, Piccinni C, De F. Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA adverse event reporting system (AERS). In: Karahoca A, editor. Data mining applications in engineering and medicine [Internet]. Rijeka, Croatia: InTech; 2012 [cited 2020 Feb 21]. Available from: http://www.intechopen.com/books/data-mining-applications-in-engineering-and-medicine/data-mining-techniques-in-pharmacovigilance-analysis-of-the-publicly-accessible-fda-adverse-event-re
5. Chandler RE. Serious neurological adverse events after ivermectin—do they occur beyond the indication of onchocerciasis? Am J Trop Med Hyg. 2018;98:382–8.
6. Kircik LH, Del Rosso JQ, Layton AM, Schauer J. Over 25 years of clinical experience with ivermectin: an overview of safety for an increasing number of indications. J Drugs Dermatol. 2016;15:325–32.
7. Aroke D, Tchouakam DN, Awuniga AT, Mapoh SY, Ngassa SN, Kadia BM. Ivermectin induced Steven-Johnsons syndrome: case report. BMC Res Notes. 2017;10:179.
8. Seeoobin K, Bueno E, Maharaj S, Ashby T, Brown M, Jones L. Toxic epidermal necrolysis after ivermectin. Am J Emerg Med. 2018;36:887–9.
9. Kerneuzet I, Blind E, Darrieux L, Moreau S, Safa G. Ivermectin-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. JAAD Case Reports. 2018;4:524–7.
10. Mancano MA. ISMP adverse drug reactions: Propofol-related infusion syndrome (PRIS)1,2; ivermectin-induced Stevens-Johnson syndrome; Stevens-Johnson syndrome/toxic epidermal necrolysis from fexofenadine; Memantine-Related Drug Eruption. Hosp Pharm. 2018;53:220–2.
11. Campillo JT, Boussinesq M, Bertout S, Faillie J-L, Chesnais CB. Serious adverse reactions associated with ivermectin: a systematic pharmacovigilance study in sub-Saharan Africa and in the rest of the world. Wanji S, editor. PLoS Negl Trop Dis. 2021;15:e0009354.
12. Saka B, Barro-Traoré F, Atadokpédé FA, Kobangué L, Niamba PA, Adégbidi H, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis in sub-Saharan Africa: a multicentric study in four countries. Int J Dermatol. 2013;52:575–9.
13. Mittmann N, Knowles SR, Koo M, Shear NH, Rachlis A, Rourke SB. Incidence of toxic epidermal necrolysis and Stevens-Johnson syndrome in an HIV cohort: an observational, retrospective case series study. Am J Clin Dermatol. 2012;13:49–54.
14. Garegnani LI, Madrid E, Meza N. Misleading clinical evidence and systematic reviews on ivermectin for COVID-19. BMJ EBM. 2021:bmjebm-2021-11090.
15. Temple C, Hoang R, Hendrickson RG. Toxic effects from Ivermectin use associated with prevention and treatment of Covid-19. N Engl J Med. 2021;385:2197–8.

How to cite this article: Bomze D, Sprecher E & Geller S. Severe cutaneous adverse reactions associated with systemic ivermectin: A pharmacovigilance analysis. J Dermatol. 2022; 49, 769–774. https://doi.org/10.1111/1346-8138.16398